Drug: EDIT-401

Preclinical

Drug: EDIT-401 is one of 3 therapeutic programs targeting Heterozygous Familial Hypercholesterolemia (HeFH). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Heterozygous Familial Hypercholesterolemia (hefh)Not yet recruiting

Heterozygous Familial Hypercholesterolemia (hefh)Preclinical

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Heterozygous Familial Hypercholesterolemia (hefh)

#DrugCompanyPhaseTrials

Lerodalcibep

LLIB Therapeutics LLC

Phase 3

1 2

Lipfendra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 3

Drug: EDIT-401

EEditas Medicine, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

PreclinicalNot yet recruiting

Heterozygous Familial Hypercholesterolemia (hefh)

NCT07894887

Clinical

Trials by Indication[1]

Heterozygous Familial Hypercholesterolemia (HeFH)1 trial

Phase 1/2 Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol

Not yet recruiting·EEditas Medicine, Inc.·Preclinical·NCT07894887·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: EDIT-401. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Drug: EDIT-401. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Editas Medicine, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: EEditas Medicine, Inc.

Drug: EDIT-401

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Heterozygous Familial Hypercholesterolemia (HeFH)1 trial

References

Drug Info

Quick Facts

Related News